Actor Josh Duhamel Featured in New Public Service Announcement for CureDuchenne
Newport Beach, Calif.
NEWPORT BEACH, Calif., November 12, 2013 – CureDuchenne, a national nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that actor Josh Duhamel is featured in a new public service announcement (PSA) on behalf of the organization.
The PSA is part of CureDuchenne’s continued efforts to raise awareness of Duchenne, a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Boys with Duchenne are usually diagnosed by the age of 5, are in a wheelchair by 12 and most don’t survive their mid-20s.
Duhamel has acted in a variety of movies and television series including Transformers, Las Vegas and All My Children. Duhamel is married to Fergie, a singer/songwriter best known as the female vocalist for The Black Eyed Peas. They recently became parents when their son Axl Jack was born. Fergie is also featured in a CureDuchenne PSA.
“We are delighted to have actor Josh Duhamel featured in a new CureDuchenne PSA,” said Debra Miller, CEO and founder, CureDuchenne. “The more people know about Duchenne and its devastating effects, the more we can raise funds for promising research to find treatments for all boys who live with Duchenne.”
The PSA can be viewed online on CureDuchenne’s website and YouTube channel. Click here to view.
is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.